Table 1.
Patient and tumour characteristics.
| Number (%) | |
|---|---|
| Age (n = 101) | |
| 65–69 years | 33 (32.7%) |
| 70–74 years | 29 (28.7%) |
| 75–79 years | 24 (23.8%) |
| 80+ years |
15 (14.8%) |
| Diagnosis (n = 101) | |
| Symptomatic | 65 (64.4%) |
| Screening |
36 (35.6%) |
| Histology (n = 101) | |
| In-situ | 11 (18.2%) |
| Ductal | 69 (.7%) |
| Lobular | 10 (3.0%) |
| Others |
11 (9.1%) |
| Grade (Invasive disease, n = 90) | |
| Grade 1 | 19 (21.1%) |
| Grade 2 | 47 (52.2%) |
| Grade 3 | 23 (25.6%) |
| Missing |
1 (1.1%) |
| Stage at diagnosis (n = 101) | |
| Stage 0 | 11 (10.9%) |
| Stage 1 | 38 (37.6%) |
| Stage 2 | 44 (43.6%) |
| Stage 3 |
8 (7.8%) |
| Tumour size (Invasive disease, n = 90) | |
| T1 | 44 (48.9%) |
| T2 | 42 (46.7%) |
| T3 | 3 (3.3%) |
| T4 |
1 (1.1%) |
| Nodal status (Invasive disease, n = 90) | |
| Positive | 20 (22.2%) |
| Negative | 70 (77.8%) |
| Lympho-vascular invasion present (Invasive disease, n = 90) |
14 (15.6%) |
| Tumour biology (Invasive disease, n = 90) | |
| Oestrogen receptor (ER) positive | 71 (78.9%) |
| Her-2 positive | 3 (3.3%) |
| ER/Her2 positive | 5 (5.6%) |
| Triple negative | 11 (12.2%) |